本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

TCR2 Therapeutics Inc.

1.48
0.0000
成交量:- -
成交額:611.75萬
市值:5,810.74萬
市盈率:-0.35
高:1.48
開:1.48
低:1.48
收:1.48
資料載入中...
2024/02/15

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/06/01

交易所摘牌聲明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2023/06/01

重要事件披露

Form 8-K - Current report
2023/06/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/06/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/06/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/06/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/06/01

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/05/31

重要事件披露

Form 8-K - Current report
2023/05/30

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2023/05/24

重要事件披露

Form 8-K - Current report
2023/05/24

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2023/05/22

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2023/05/22

重要事件披露

Form 8-K - Current report
2023/05/11

重要事件披露

8-K - Current report
2023/05/11

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/05/05

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/03/23

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2023/03/23

重要事件披露

8-K - Current report
2023/03/23

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]